Anti-IgE therapy for allergic bronchopulmonary aspergillosis

Journal of Microbiology, Immunology and Infection

Volumn 49, Issue 3, 2016, Pages 459-463

  Homma, Tetsuya ^a   Kurokawa, Masatsugu ^a   Matsukura, Satoshi ^a   Yamaguchi, Munehiro ^a   Adachi, Mitsuru ^a  

^a SHOWA UNIVERSITY   (Japan)

Author keywords

Allergic bronchopulmonary aspergillosis; IgE; Omalizumab; Prednisolone; Severe asthma

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE; IMMUNOGLOBULIN E ANTIBODY; ITRACONAZOLE; OMALIZUMAB; PRANLUKAST; PREDNISOLONE; SALMETEROL; THEOPHYLLINE; ANTI-IGE ANTIBODIES; ANTIASTHMATIC AGENT; ANTIFUNGAL AGENT; ANTIIDIOTYPIC ANTIBODY;

ADULT; ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; ARTICLE; ASTHMA; BRONCHIECTASIS; CASE REPORT; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; LUNG INFILTRATE; MALE; MIDDLE AGED; ADOLESCENT; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MICROBIOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIFUNGAL AGENTS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; OMALIZUMAB; YOUNG ADULT;

EID: 84888232100     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2013.10.003     Document Type: Article

References (22)

1. 1 Ohta, K., Yamaguchi, M., Akiyama, K., Adachi, M., Ichinose, M., Takahashi, K., et al. Japanese guideline for adult asthma. Allergol Int 58 (2011), 115–145.
2. 2 Agarwal, R., Aggarwal, A.N., Gupta, D., Jindal, S.K., Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis 13 (2009), 936–944.
3. 3 Simmonds, N.J., Cullinan, P., Hodson, M.E., Growing old with cystic fibrosis - the characteristics of long-term survivors of cystic fibrosis. Respir Med 103 (2009), 629–635.
4. 4 Murdock, B.J., Shreiner, A.B., McDonald, R.A., Osterholzer, J.J., White, E.S., Toews, G.B., et al. Coevolution of TH1, TH2, and TH17 responses during repeated pulmonary exposure to Aspergillus fumigatus conidia. Infect Immun 79 (2011), 125–135.
5. 5 Rosenberg, M., Patterson, R., Mintzer, R., Cooper, B.J., Roberts, M., Harris, K.E., Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med 86 (1977), 405–414.
6. 6 Stevens, D.A., Schwartz, H.J., Lee, J.Y., Moskovitz, B.L., Jerome, D.C., Catanzaro, A., et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 342 (2000), 756–762.
7. 7 Tillie-Leblond, I., Germaud, P., Leroyer, C., Tetu, L., Girard, F., Devouassoux, G., et al. Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66 (2011), 1254–1256.
8. 8 Pérez-de-Llano, L.A., Vennera, M.C., Parra, A., Guallar, J., Marin, M., Asensio, O., et al. Effects of omalizumab in Aspergillus-associated airway disease. Thorax 66 (2011), 539–540.
9. 9 Rodrigo, G.J., Neffen, H., Castro-Rodriguez, J.A., Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 139 (2011), 28–35.
10. 10 Corren, J., Shapiro, G., Reimann, J., Deniz, Y., Wong, D., Adelman, D., et al. Allergen skin tests and free IgE levels during reduction and cessation of omalizumab therapy. J Allergy Clin Immunol 121 (2008), 506–511.
11. 11 van der Ent, C.K., Hoekstra, H., Rijkers, G.T., Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62 (2007), 276–277.
12. 12 Zirbes, J.M., Milla, C.E., Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 43 (2008), 607–610.
13. 13 Kanu, A., Patel, K., Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 43 (2008), 1249–1251.
14. 14 Lebecque, P., Leonard, A., Argaz, M., Godding, V., Pilette, C., Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. BMJ Case Rep, 2009, 2009 bcr07.2008.0379.
15. 15 Randhawa, I., Chin, T., Nussbaum, E., Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 46 (2009), 445–447.
16. 16 Brinkmann, F., Schwerk, N., Hansen, G., Ballmann, M., Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 65 (2010), 134–135.
17. 17 Elmallah, M.K., Hendeles, L., Hamilton, R.G., Capen, C., Schuler, P.M., Management of patients with cystic fibrosis and allergic bronchopulmonary aspergillosis using anti-immunoglobulin e therapy (omalizumab). J Pediatr Pharmacol Ther 17 (2012), 88–92.
18. 18 Wong, R., Wong, M., Robinson, P.D., Fitzgerald, D.A., Omalizumab in the management of steroid dependent allergic bronchopulmonary aspergillosis (ABPA) complicating cystic fibrosis. Paediatr Respir Rev 14 (2013), 22–24.
19. 19 Lin, R.Y., Sethi, S., Bhargave, G.A., Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma 47 (2010), 942–945.
20. 20 Collins, J., Devos, G., Hudes, G., Rosenstreich, D., Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma Allergy 5 (2012), 65–70.
21. 21 Sastre, I., Blanco, J., Mata, H., García, F., A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 22 (2012), 145–147.
22. 22 Limb, S.L., Starke, P.R., Lee, C.E., Chowdhury, B.A., Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 120 (2007), 1378–1381.